40 results about "Predictive marker" patented technology

The invention belongs to the field of biomedicine, and particularly relates to application of CRYL1 protein in preparation of a product for evaluation, diagnosis or auxiliary diagnosis of postoperative recurrence risk of calcium oxalate kidney stone combined with renal nipple calcium spot, and the sequence of the CRYL1 protein is shown as SEQ ID NO.1. The invention discovers that the expression of the CRYL1 protein in renal tubules and collecting tube cells of renal papillary calcium spot tissues is reduced for the first time, and tests prove that the urine CRYL1 protein is a predictive factor and a predictive marker for postoperative recurrence of a patient with CaOx kidney stone combined with renal papillary calcium spot. The CRYL1 protein detection kit is further researched and developed to be used for detecting or evaluating the postoperative recurrence risk of patients suffering from CaOx kidney stone combined with renal nipple calcium spots, personalized follow-up visit and prevention schemes of the patients are promoted, and the CRYL1 protein detection kit has huge clinical application prospects.

The invention discloses intestinal bacteria and serum metabolites which can be used as biomarkers of type 2 diabetes mellitus (prediabetes mellitus (PDM), new diagnosis diabetes mellitus (NDDM) and diabetes mellitus (P2DM) after medication) in different disease stages, and application of the intestinal bacteria and the serum metabolites. Aiming at type 2 diabetes mellitus, predictive markers including staphylococcus aureus, escherichia coli, klebsiella pneumoniae, branched chain amino acids (leucine, valine and isoleucine) and the like, especially staphylococcus aureus of which the genome contains acetolactate synthase (ALS), are efficiently screened out. The type 2 diabetes mellitus marker disclosed by the invention can be used for early warning the illness risk of type 2 diabetes mellitus and guiding the adjustment of an intestinal microbial environment; the method can be used for indicating the correlation between the intestinal microbial environment and the type 2 diabetes mellitus and is used for assisting diagnosis; and drug action target research, accurate medication, pathogenesis research and the like are realized.

The invention discloses a prediction marker and a prediction method for acute upper respiratory infection susceptibility. The prediction marker and the prediction method are used for solving the problem that current acute upper respiratory infection susceptibility risk prediction is low in accuracy. The method comprises the following steps: firstly, providing a prediction marker for acute upper respiratory infection susceptibility, wherein the prediction marker is a prediction feature combination obtained by comprehensively considering human health state blood routine data and baseline blood transcriptome data and carrying out feature processing; secondly, providing a prediction method, and obtaining a to-be-detected blood sample; and performing blood analysis based on a to-be-detected blood sample, inputting the obtained blood routine sample and the gene expression sample into a susceptibility prediction model pre-trained based on a prediction marker for susceptibility risk judgment, and obtaining a susceptibility risk assessment result of acute upper respiratory infection of a human body corresponding to the to-be-detected blood sample in a future period of time, therefore, the acute upper respiratory infection susceptibility risk of the human body in a period of time in the future can be simply, quickly and accurately predicted.

The present disclosure provides a method and a gene detection panel for evaluating treatment response, recurrence and survival by detecting genetic variants and their changes before and after concurrent chemoradiotherapy in tumor tissues of patients with esophageal cancer. The present disclosure develops a set of esophageal cancer NGS analysis panel. Aiming at 402 mutation sites including 35 genes that frequently occur in esophageal squamous cell carcinoma tissue cells, 62 pairs of esophageal squamous cell carcinoma tissues before and after CCRT are analyzed for specific site variation, hoping to find new predictive markers. The present disclosure combines these potential markers into an esophageal cancer detection panel, which has extremely high value for improving the prognosis of esophageal cancer.

The objective of the present invention is to provide a disease onset risk prediction device for predicting the onset risk of liver disease from disease-related information about a subject of prediction.　A disease onset risk prediction device according to the present invention includes an information acquisition unit, a prediction unit, and an output unit, wherein: the information acquisition unit acquires disease-related information about a subject of prediction, the disease being liver disease, and the disease-related information including at least one among information acquired by health diagnosis and information acquired by the subject of prediction; the prediction unit predicts a disease onset risk of the subject of prediction from the disease-related information; and the output unit outputs the disease onset risk.

The invention discloses a PCI postoperative MACE risk prediction marker for an acute ST segment elevation type myocardial infarction patient, and belongs to the field of biological medicine. The application comprises application of a reagent for detecting the lipid metabolism marker in preparation of a kit for predicting the risk of main adverse cardiovascular events after the PCI operation of a patient suffering from the acute ST segment elevation type myocardial infarction, and the reagent for detecting the lipid metabolism marker comprises glycodeoxycholic acid, [(2R)-3-[(6Z, 9Z, 12Z)-octadeca-6, 9, 10-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, the detection reagent is selected from one or more of a detection reagent for N-((2S, 3R)-1, 3-dihydroxy octadecane-4-alkene-2-yl) acetamide, a detection reagent for 2-(2, 6, 7, 12-trienoyl) oxy-2-[(Z)-octadecane-9-enoyl] oxypropyl] 2-(trimethyl ammonium) ethyl phosphate, 8-hydroxy-8-(3-octyl oxirane-2-yl) octanoic acid and N-((2S, 3R)-1, 3-dihydroxy octadecane-4-alkene-2-yl) acetamide. The four lipid metabolism markers (C44H80NO8P, C18H34O4, C20H39NO3 and C26H43NO5) screened by the invention are used for the prediction efficiency of MACE prediction, the sensitivity of the four lipid metabolism markers reaches 0.889, the specificity of the four lipid metabolism markers is 0.894, the AUC of the four lipid metabolism markers is 0.921, and the four lipid metabolism markers have high sensitivity and high specificity.

The purpose of the present disclosure is to provide a disease onset risk prediction device for predicting the risk of onset of a renal disease on the basis of disease-related information of a prediction subject.　This disease onset risk prediction device includes an information acquisition unit, a prediction unit, and an output unit. The information acquisition unit acquires disease-related information of a prediction subject, the disease being a renal disease. The disease-related information includes at least one of information acquired by a health diagnosis and information acquired by the prediction subject. The prediction unit predicts a disease onset risk of the prediction subject from the disease-related information, and the output unit outputs the disease onset risk.

The invention discloses application of Keratin5 low expression and PADI3 nuclear translocation in serving as a predictive marker for invasion and metastasis of head and neck squamous cell carcinoma, belongs to the technical field of biological medicine, verifies clinical applicability of KRT5 low expression and / PADI3 nuclear translocation (namely KRT5low / PADI3nucle) serving as a predictive index so as to fill the blank of the prior art, and provides a novel predictive marker for invasion and metastasis of head and neck squamous cell carcinoma. A novel molecular marker and an intervention target spot are provided for precise diagnosis and treatment of the head and neck squamous cell carcinoma; the KRT5 and PADI3 co-expression region forms a specific micro-domain difference and a specific mode in tumor tissues, can be used as an effective head and neck squamous cell carcinoma metastasis prediction marker, and has important scientific significance and application value for optimizing clinical diagnosis and treatment strategies.

The purpose of the present invention is to provide a disease onset risk prediction device for predicting the risk of onset of a skeletal disease or joint disease from disease-related information of a prediction target individual.　The disease onset risk prediction device according to the present disclosure comprises an information acquisition unit, a prediction unit, and an output unit, wherein: the information acquisition unit acquires disease-related information of a prediction target individual; the disease is a skeletal disease or a joint disease; the disease-related information includes at least one of information acquired through a medical checkup and information acquired by the prediction target individual; the prediction unit predicts the risk of onset of the disease in the prediction target individual from the disease-related information; and the output unit outputs the disease onset risk.

The present invention provides various methods for screening one or more compounds, suitably using non-invasive visual methods and neural networks for generating predicted fluorescence images of cells, to assess an effect of the compound on the cell, as well as to classify a compound or to determine an activity of a compound. Also provided are systems and methods for carrying out such assessments.

The invention discloses an application of intestinal flora metabolite salicylic acid as a predictive marker of Escherichia coli calf diarrhea. The obviously up-regulated metabolite salicylic acid is screened out from the diarrhea calf feces through a non-targeted metabonomics technology, and in a group of new independent samples, it is verified through an ELISA test that the salicylic acid concentration of the diarrhea calf feces is obviously higher than that of a healthy group. ROC curve analysis shows that the area under curve (AUC) of SA for predicting escherichia coli calf diarrhea is 0.8148, and the method has good prediction capability. The invention provides a non-invasive, cheap, rapid and high-specificity prediction method, can be used for early warning and auxiliary diagnosis of Escherichia coli calf diarrhea, and has important significance for guiding clinical precise medication and reducing the death rate of calves.

The present disclosure provides improved methods of treating endometrial cancer or ovarian cancer in a subject using levels of combinations of biomarkers as predictive markers for response to CDK2 inhibitors and combinations with CDK2 inhibitors.

The present disclosure provides improved methods of treating endometrial cancer or ovarian cancer in a subject using levels of combinations of biomarkers as predictive markers for response to CDK2 inhibitors and combinations with CDK2 inhibitors.

The present invention provides a gene detection method and kit for detecting tumor tissue gene variation and changes before and after synchronized radiotherapy to perform therapeutic response, recurrence and survival assessment of esophageal cancer patients. The invention develops an esophageal cancer NGS analysis kit. According to 402 variation sites containing 35 genes frequently occurring in esophageal squamous epithelial cell carcinoma tissue cells, 62 specific site variation of tissues before and after esophageal squamous epithelial cell carcinoma CCRT is analyzed, and it is expected that a new prediction marker can be found. The potential markers are combined into an esophageal cancer detection kit, and the kit has extremely high value for improving the prognosis of esophageal cancer.

The purpose of the present disclosure is to provide a disease onset risk prediction device for predicting the onset risk of an endocrine disease or a metabolic disease from disease-related information regarding a prediction subject.　A disease onset risk prediction device according to the present disclosure includes an information acquisition unit, a prediction unit and an output unit. The information acquisition unit acquires disease-related information regarding a prediction subject. The disease is an endocrine disease or a metabolic disease. The disease-related information contains at least one of information acquired by a health diagnosis and information acquired by the prediction subject. The prediction unit predicts a disease onset risk of the prediction subject from the disease-related information, and the output unit outputs the disease onset risk.

The purpose of the present disclosure is to provide a disease onset risk prediction device for predicting an onset risk of a heart disease or a vascular system disease from disease-related information of a target to be predicted.　A disease onset risk prediction device according to the present disclosure includes an information acquisition unit, a prediction unit, and an output unit. The information acquisition unit acquires disease-related information of a target to be predicted. The disease is a heart disease or a vascular system disease. The disease-related information includes at least one of information acquired from a medical examination and information acquired from the target to be predicted. The prediction unit predicts a disease onset risk of the target to be predicted from the disease-related information. The output unit outputs the disease onset risk.

The present invention relates to the use of soluble CD27 as a biomarker to predict response to immune checkpoint inhibitor treatment. The inventors have collaborated with two queues of patients and have identified a soluble marker CD27 present in the plasma of renal cell carcinoma patients, the pre-treatment concentration of which can predict a response against PD-1 / PD-L1. The marker is more like a predictive marker of response to anti-PD-1 / PD-L1 therapy, rather than as a prognostic marker. In fact, it is independent of a better survival rate of metastatic renal cell carcinoma patients receiving treatment with anti-angiogenic agents. The markers are not associated with conventional clinical severity markers that classify metastatic kidney cancer patients.

The invention discloses a predictive marker as well as a related product and application thereof, and relates to the field of tumor diagnosis. The invention finds that WNT5A can be used as a marker of any one or more of disease risk, prognosis risk, disease progress, treatment effect, residual focus and metastatic focus of squamous-cell carcinoma, is beneficial to accurate diagnosis and treatment of squamous-cell carcinoma, and accelerates the research and development of new drugs.

The object of the present invention is the use of glycosphingolipid biosynthesis inhibitors for the treatment of tumors that are dependent on the oncogene GOLPH3 as well as on two oncogenes similar to GOLPH3 (GOLPH3-L and LCS, which form a GOLPH3 cluster with GOLPH3). Another object of the invention is the use of GOLPH3 genomic amplification detection as a predictive marker for identifying tumors responsive to said inhibitor.

The invention belongs to the technical field of biological medicine, and discloses application of a CRM1-PROM2 signal axis inhibitor in preparation of a gastric cancer cell ferroptosis inducer sensitizer, an anti-gastric cancer drug and a predictive marker. In the application provided by the invention, the CRM1-PROM2 signal axis is destroyed or inhibited by the CRM1-PROM2 signal axis inhibitor, so that the level of PROM2 in gastric cancer cytoplasm can be reduced, and then downstream KEAP1 / NRF2, FPN iron ion efflux and other ferroptosis resistance related signal axes are interfered, so that the ferroptosis sensitivity of gastric cancer cells is improved, and the treatment effect of the ferroptosis inducer on gastric cancer is enhanced; and the inhibitor shows certain targeting property in the aspect of enhancing the treatment effect of the ferroptosis inducer on the gastric cancer, and has important significance in realizing accurate diagnosis and treatment of the gastric cancer.

The invention particularly discloses a predictive marker for treating acute myelogenous leukemia on double-negative T cells, and relates to the technical field of biological medicines. The CD96 can be used as an intervention target point insensitive to DNT treatment of the AML patient, the killing effect of DNT on primary cells of the AML patient can be enhanced by specifically knocking out the CD96 or combining the CD96 with a CD96 specific blocking agent Nelistotug, and the insensitivity of DNT treatment of the AML patient is improved.

The invention discloses a predictive marker for improving the blood sugar effect through exercise intervention of a type 2 diabetes patient and application of the predictive marker. The predictive marker is formed by combining the following metabolite markers: creatine, spermidine, 4-oxo-tretinoin, S-methylcysteine sulfoxide, 3-phosphoglyceric acid / 2-phosphoglycerol, vitamin C3-sulfosulfone, salicyloyl urea glucuronide and gamma-glutamyl isoleucine, and the metabolite markers are used for detecting the content of the metabolite markers. The method is used for predicting the movement intervention of overweight or obese type 2 diabetes patients to improve the blood sugar obviously, the treatment efficiency is improved, and the application of precision medicine in type 2 diabetes management is realized.

The invention relates to an ankylosing spondylitis curative effect prediction marker of an interleukin 17A inhibitor and application of the ankylosing spondylitis curative effect prediction marker. The marker for predicting the curative effect of the ankylosing spondylitis of the interleukin 17A inhibitor, disclosed by the invention, comprises a lysosome related membrane protein 3 (LAMP3) and 11 beta-hydroxysteroid dehydrogenase (HSD11B1).

The disclosure describes the use of predictive markers in methods for prognosing the response to a Coenzyme Q10 treatment for pancreatic cancer in a subject, and methods for method of treating pancreatic cancer based on the prognostic information.

The invention belongs to the technical field of biological medicine, and provides an immunotherapy response prediction marker RBM28 and application thereof in combined treatment sensitization, the application is characterized in that the expression level of RBM28 is used as an evaluation index, a TG003 and PD-1 or ATO and PD-1 combined inhibitor is used for in-vitro treatment of esophageal squamous carcinoma tumor cells and mouse models, and the immunotherapy response prediction marker RBM28 can be used for immunotherapy sensitization. The immunotherapy prediction effect of the RBM28 expression level as an evaluation index on the esophageal squamous cell carcinoma and the treatment effect of the TG003 and PD-1 or ATO and PD-1 combined inhibitor on the esophageal squamous cell carcinoma are evaluated; results show that high expression of RBM28 is related to development of various tumors, and RBM28 can be used as an immunotherapy response prediction marker; the inhibitor can be used for jointly treating esophageal squamous cell carcinoma, inhibiting RBM28 phosphorylation, inducing immune activation, enhancing the curative effect of immunotherapy and remarkably reducing the tumor volume so as to achieve the purpose of treating esophageal squamous cell carcinoma.

The disclosure describes the use of predictive markers in methods for prognosing the response to a Coenzyme Q10 treatment for pancreatic cancer in a subject, and methods for method of treating pancreatic cancer based on the prognostic information.

The invention belongs to the field of biological medicine, and particularly relates to ICAM1 serving as a marker for predicting the therapeutic effect of a glioblastoma PD-1 monoclonal antibody and combined therapy application of the ICAM1. The ICAM1 not only can be used as a potential biomarker for predicting the treatment effect of the anti-PD-1 antibody, but also can be used as an important target in a combined immunotherapy strategy; the ICAM1 antibody and PD-1 monoclonal antibody combined treatment can become a novel immune intervention means for improving the prognosis of GBM patients. Therefore, the ICAM1 can be used as a predictive marker for the treatment effect of the glioblastoma PD-1 monoclonal antibody, and the ICAM1 blocking and combining with the PD-1 monoclonal antibody has high clinical transformation value.